EC Clinical and Medical Case Reports

Research Article Volume 6 Issue 7 - 2023

The EW Peptide Regulates Gene Expression and HIF1α Protein Synthesis in Patients with Diabetic Foot

Vladimir Khavinson1,2, Natalia Linkova1*, Svetlana Trofimova1, Natalia Fridman1 and Michael Petukhov3

1Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, Saint Petersburg, Russia

2Group of Peptide Regulation of Aging, Pavlov Institute of Physiology of Russian Academy of Sciences, Saint Petersburg, Russia

3Petersburg Nuclear Physics Institute Named After B.P. Konstantinov, NRC “Kurchatov Institute”, Gatchina, Russia

*Corresponding Author: Natalia Linkova, Department of Biogerontology, Saint Petersburg Institute of Bioregulation and Gerontology, Saint Petersburg, Russia.
Received: May 30, 2023; Published: June 15, 2023

The immunomodulatory drug Thymogen (EW peptide) regulates the reactions of cellular, humoral immunity and nonspecific resistance of the body. The EW peptide was previously shown to be effective in the repair of lower extremity ulcers in patients with diabetes mellitus. This correlated with the normalization of the HIF1α protein concentration in blood plasma. The aim of this work is to elucidate the molecular mechanism of the EW peptide’s effect on the synthesis of HIF1α. Molecular modeling and ligand docking methods were used to demonstrate the possibility of binding the EW peptide to the double-stranded DNA sequences GGAG, AGGA, CCGG, GGTG, AGTC in various HIF1α gene promoters. These data suggest that the clinical efficacy of the EW peptide in diabetic foot patients is due to its ability to regulate gene expression and HIF1α protein synthesis.

Keywords: EW Peptide; HIF1α; Hypoxia; Diabetes Mellitus; Diabetic Foot

  1. Wong YH., et al. “Genetic associated complications of type 2 diabetes mellitus”. Panminerva Medica 2 (2022): 274-288.
  2. Catrina SB., et al. “Hypoxia and hypoxia-inducible factors in diabetes and its complications”. Diabetologia4 (2021): 709-716.
  3. Khedr S., et al. “Effects of tryptophan-containing peptides on angiotensin-converting enzyme activity and vessel tone ex vivo and in vivo”. European Journal of Nutrition 3 (2018): 907-915.
  4. Shibata S., et al. “Effects of the dipeptide L-glutamic acid-L-tryptophan on dermatitis in mice and human keratinocytes”. Heliyon 8 (2022): e08729.
  5. Smith DL., et al. “Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan”. International Journal of Cancer 106 (2003): 528-533.
  6. Patil PJ., et al. “Exploring bioactive peptides as potential therapeutic and biotechnology treasures: A contemporary perspective”. Life Sciences 301 (2022): 120637.
  7. Trofimova S., et al. “Peptide Correction of Tissue Hypoxia in Diabetic Foot Syndrome”. EC Clinical and Medical Case Reports 5 (2022): 8-15.
  8. Trofimov AV., et al. “Medical preparation and method for enhancing tissue oxygenation in case of diabetic foot”. USA Patent US (2021).
  9. Khavinson VK and Malinin VV. “Gerontological Aspects of Genome Peptide Regulation”. Karger AG: Basel, Switzerland (2005): 1-104.
  10. Khavinson VK., et al. “Peptide Regulation of Gene Expression: A Systematic Review”. Molecules 26 (2021): 7053.
  11. Kolchina N., et al. “Systematic search for structural motifs of peptide binding to double-stranded DNA”. Nucleic Acids Research 47 (2019): 10553-10563.
  12. Arnautova YA., et al. “Development of a new physics-based internal coordinate mechanics force field and its application to protein loop modeling”. Proteins 79 (2011): 477-498.
  13. Abagyan R and Totrov M. "Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins". Journal of Molecular Biology 235 (1994): 983-1002.
  14. Lukashev D and Sitkovsky M. “Preferential expression of the novel alternative isoform I.3 of hypoxia-inducible factor 1alpha in activated human T lymphocytes”. Human Immunology 7 (2008): 421-425.

Vladimir Khavinson., et al. "The EW Peptide Regulates Gene Expression and HIF1α Protein Synthesis in Patients with Diabetic Foot." EC Clinical and Medical Case Reports   6.7 (2023): 146-151.